POLB — Poolbeg Pharma Share News
0.000.00%
Last trade - 00:00PDMR Notification
Brief: Poolbeg Pharma Says FDA Feedback Broadly Aligned With Development Pathway For POLB 001
Brief: Poolbeg Pharma Announces Granted POLB 001 Cancer Immunotherapy-Induced CRS Patent In Canada
Annual Report & AGM Notice
Results for the year ended 31 December 2025
Appointment of Dr Adrian Kilcoyne to SAB
Notification of Major Holdings
Exercise of Options & Total Voting Rights
Letter to Shareholders – 2025 a year of progress
POLB 001 to feature in CRS research programme
Interim Results for the six months to 30 June 2025
POLB 001 Phase 2a Trial Update
Notification of Major Holdings
Notification of Major Holdings
Director/PDMR Shareholding
Brief: Poolbeg Granted FDA Orphan Drug Designation For POLB 001
Annual Report, AGM Notice & Circular
Result of upsized oversubscribed BookBuild Offer
Increase of BookBuild Offer